Atypical Hemolytic Uremic Syndrome Treatment Market Report 2026

The atypical hemolytic uremic syndrome treatment market size has grown strongly in recent years. It will grow from $1.73 billion in 2025 to $1.86 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rare disease diagnosis growth, plasma exchange adoption, kidney failure cases, biologic drug approvals, hospital nephrology expansion.

The atypical hemolytic uremic syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $2.46 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to precision medicine adoption, complement pathway research, orphan drug incentives, genetic screening programs, biologics innovation. Major trends in the forecast period include increased use of complement inhibitor therapy, growth of genetic diagnostic testing, expansion of long-term disease management, rising adoption of targeted biologics, focus on rare disease treatment access.

The rising demand for targeted therapies is expected to propel the growth of the atypical hemolytic uremic syndrome treatment market going forward. Targeted therapies refer to the medical treatments that specifically target and interfere with molecular pathways involved in the growth and spread of diseases. The rising demand for targeted therapies is due to their ability to provide more precise treatments with fewer side effects, improve patient outcomes, and offer alternatives to traditional, less specific therapies. Atypical hemolytic uremic syndrome (aHUS) treatment supports targeted therapies by specifically blocking the overactivation of the complement system, which is the root cause of the disease, allowing for precise intervention that minimizes damage to blood vessels and kidneys. For instance, in October 2023, according to NHS England, a UK-based government agency, in England, 11 million hormone replacement therapy (HRT) items were prescribed, up 47% from 2021-22, with around 2.3 million patients receiving prescriptions, marking a 29% year-on-year increase. Therefore, the rising demand for targeted therapies is driving growth in the atypical hemolytic uremic syndrome treatment market.

Leading companies in the atypical hemolytic uremic syndrome (aHUS) treatment market are focusing on developing innovative therapies, such as monoclonal antibody drugs, to enhance targeted complement inhibition and improve patient outcomes. Monoclonal antibody drugs are lab-engineered proteins that mimic the immune system’s ability to combat harmful agents by selectively targeting and binding to specific proteins involved in disease processes. For example, in January 2025, AstraZeneca Pharma India Limited, an India-based biopharmaceutical company, received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, sell, and distribute eculizumab (marketed as Soliris) in India. These monoclonal antibodies specifically bind to complement protein C5, preventing its cleavage and thereby blocking the formation of the terminal complement complex responsible for immune-mediated cell damage. Eculizumab is used to treat rare and severe conditions, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis, and neuromyelitis optica spectrum disorder, by preventing complement-mediated tissue injury.

In October 2024, 3billion Inc., a South Korea-based precision medicine and genetic diagnostics company, formed a partnership with AstraZeneca Korea to transform genetic diagnosis for atypical hemolytic uremic syndrome (aHUS). Through this collaboration, 3billion aims to utilize its advanced whole genome sequencing and AI-driven variant interpretation platform alongside AstraZeneca Korea’s clinical expertise to enhance early detection, accurate diagnosis, and treatment decision-making for aHUS patients. AstraZeneca Korea, based in South Korea, provides medications for atypical hemolytic uremic syndrome.

Major companies operating in the atypical hemolytic uremic syndrome treatment market are F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Alnylam Pharmaceuticals Inc., Vifor Pharma Ltd., Samsung Bioepis Co. Ltd., Fuji Pharma Co. Ltd., Aevitas Therapeutics Inc., Pharmasyntez JSC, Omeros Corporation, ChemoCentryx Inc., ISU Abxis Co. Ltd., Greenovation Biotech GmbH, Akari Therapeutics plc, NovelMed Therapeutics Inc., Eleva GmbH.

North America was the largest region in the atypical hemolytic uremic syndrome treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atypical hemolytic uremic syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atypical hemolytic uremic syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the atypical hemolytic uremic syndrome treatment market by increasing the cost of imported biologics, monoclonal antibody APIs, and advanced diagnostic components. These impacts have been most pronounced in complement inhibitor therapy segments, particularly in north america and europe. Asia-pacific markets have experienced pricing pressures. However, tariffs have encouraged localized biologic manufacturing and rare disease treatment infrastructure development.

The atypical hemolytic uremic syndrome treatment market research report is one of a series of new reports that provides atypical hemolytic uremic syndrome treatment market statistics, including atypical hemolytic uremic syndrome treatment industry global market size, regional shares, competitors with a atypical hemolytic uremic syndrome treatment market share, detailed atypical hemolytic uremic syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the atypical hemolytic uremic syndrome treatment industry. This atypical hemolytic uremic syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening disorder marked by abnormal blood clotting that damages small blood vessels, leading to hemolytic anemia, low platelet counts, and kidney injury. It is usually caused by genetic mutations or complement system dysregulation, resulting in uncontrolled inflammation and vascular damage.

The primary treatments for atypical hemolytic uremic syndrome include complement inhibitors, plasma exchange therapy, supportive care, and antibiotics. Complement inhibitors are therapeutic agents that block or regulate the activation of the complement system, a critical part of the immune system involved in inflammation, immune responses, and cell lysis. These treatments can be administered intravenously, subcutaneously, or orally. Key technologies associated with treatment include genetic testing and diagnostic tools, real-time monitoring and complement activation technologies, treatment delivery systems, and digital health solutions. These are utilized by a range of end users, including specialty clinics, home care settings, and ambulatory care centers.

The atypical hemolytic uremic syndrome (aHUS) market consists of revenues earned by entities by providing services such as renal support and dialysis, genetic testing and counseling, long-term monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The atypical hemolytic uremic syndrome (aHUS) market also includes sales of immunosuppressive therapies, plasma exchange equipment, dialysis machines, and supportive care medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.